Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-12-21
pubmed:abstractText
Psoriatic arthritis (PsA) is an inflammatory joint disease, in which early neovascularization of affected skin and synovial tissue represents an important pathogenetic step in the disease process. Activation of the peroxisome proliferator activated receptor gamma (PPARgamma) showed anti-inflammatory effects in several in vitro and in vivo models (e.g. collagen-induced arthritis) by inhibition of angiogenesis and suppression of proinflammatory cytokines. Therefore, we studied the use of pioglitazone, a PPARgamma agonist originally developed for the treatment of diabetes, in patients with PsA.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1462-0324
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
126-9
pubmed:dateRevised
2007-9-6
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
pubmed:affiliation
Department of Internal Medicine I, University of Regensburg, Germany. bongartz.tim@mayo.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't